About adagene - ADAG
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.
ADAG At a Glance
Adagene, Inc.
Suzhou Industrial Park
Suzhou, Jiangsu 215123
| Phone | 86-512-8777-3632 | Revenue | 103.26K | |
| Industry | Pharmaceuticals: Major | Net Income | -33,440,875.81 | |
| Sector | Health Technology | Employees | 138 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ADAG Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 867.848 |
| Price to Book Ratio | 1.856 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.654 |
| Enterprise Value to Sales | 221.872 |
| Total Debt to Enterprise Value | 0.807 |
ADAG Efficiency
| Revenue/Employee | 748.23 |
| Income Per Employee | -242,325.187 |
| Receivables Turnover | 12.427 |
| Total Asset Turnover | 0.001 |
ADAG Liquidity
| Current Ratio | 2.299 |
| Quick Ratio | 2.299 |
| Cash Ratio | 2.231 |
ADAG Profitability
| Gross Margin | -797.492 |
| Operating Margin | -34,835.421 |
| Pretax Margin | -32,403.457 |
| Net Margin | -32,386.449 |
| Return on Assets | -32.622 |
| Return on Equity | -55.236 |
| Return on Total Capital | -48.453 |
| Return on Invested Capital | -49.412 |
ADAG Capital Structure
| Total Debt to Total Equity | 36.604 |
| Total Debt to Total Capital | 26.795 |
| Total Debt to Total Assets | 20.712 |
| Long-Term Debt to Equity | 1.108 |
| Long-Term Debt to Total Capital | 0.811 |